A hep c screening is a blood test that detects the presence of hepatitis C virus (HCV) antibodies or viral RNA. It identifies infection early, often before symptoms develop, allowing timely medical intervention to prevent liver disease.
Hepatitis C is a viral infection that attacks the liver. Left untreated, it can lead to cirrhosis, liver failure, or liver cancer. The Centers for Disease Control and Prevention (CDC) recommends one-time screening for all adults aged 18 to 79, regardless of risk factors, due to high rates of undiagnosed cases.
Screening uses two primary methods: antibody testing and nucleic acid testing (NAT). Antibody tests detect past or current infection. NAT detects active virus in the bloodstream. A positive antibody result requires NAT confirmation to determine if the infection is still active.
The process begins with a blood draw. A healthcare provider collects a small sample from a vein in the arm. The lab analyzes the sample for HCV-specific antibodies or genetic material.
Antibody tests return results in 15 to 30 minutes. They indicate whether the immune system has produced antibodies against HCV. This suggests exposure, but not necessarily current infection. About 15% of people exposed to HCV clear the virus naturally within six months without treatment.
If the antibody test is positive, a follow-up NAT is required. NAT measures viral load-the amount of HCV RNA in the blood. A positive NAT confirms active infection. The CDC reports that approximately 75% of people with positive antibody tests have ongoing viremia and require treatment.
Two main test types serve different purposes in diagnosis and monitoring:
| Test Type | Purpose | Result Time | Used When |
|---|---|---|---|
| Anti-HCV antibody test | Detects past or current infection | 15-30 min | Initial screening for all adults |
| NAT (HCV RNA test) | Confirms active infection | 2-5 days | After positive antibody result |
Some clinics offer rapid point-of-care tests that deliver results in under 20 minutes. These are useful in community health settings, such as mobile clinics or harm reduction programs, where immediate counseling and linkage to care are critical.
Home testing kits are available but require confirmation through clinical labs. The FDA-approved OraQuick HCV Rapid Test uses oral fluid, though it's less sensitive than blood-based assays. Positive results must be confirmed with a blood test.
Approximately 2.4 million people in the U.S. live with chronic hepatitis C, according to the CDC. Over half are unaware of their status. Early detection through screening reduces transmission and prevents long-term complications.
Untreated HCV leads to fibrosis (scarring) in 20% of infected individuals within 10 years. By 20 years, about 30% develop cirrhosis. Liver cancer risk increases fivefold among those with cirrhosis. Screening interrupts this progression.
Direct-acting antivirals (DAAs) cure over 95% of cases in 8 to 12 weeks. Treatment is most effective when started early. The National Institutes of Health (NIH) states that treating patients before significant liver damage occurs improves survival and reduces healthcare costs.
Many assume hep c screening is only for people who inject drugs. This is incorrect. The CDC now recommends universal screening for all adults because many infections occur through unknown routes, including blood transfusions before 1992.
Another myth is that symptoms indicate infection. Most people with acute HCV show no signs. When symptoms do appear-fatigue, jaundice, dark urine-they typically emerge months after initial exposure. By then, liver damage may already be underway.
A key distinction: a negative screening result doesn't rule out recent infection. Window periods for antibody tests can last up to 6 months. NAT can detect infection as early as 2 weeks post-exposure. If someone has a known exposure and feels unwell, repeat testing after 3 months is advised.
In 2021, a 45-year-old man visited his primary care provider for a routine physical. He had no history of IV drug use, tattoos, or risky sexual behavior. His doctor ordered a standard hep c screening as part of the annual wellness exam.
The antibody test came back positive. A follow-up NAT confirmed active HCV RNA at 120,000 IU/mL. He was referred to a hepatologist. After evaluation, he began treatment with a single DAA regimen-sofosbuvir/velpatasvir-for 12 weeks.
At week 12, a repeat NAT showed undetectable viral load. He achieved sustained virologic response (SVR), meaning the virus remained suppressed 12 weeks after treatment ended. He was cured. His liver enzymes normalized, and he reported improved energy levels.
This case illustrates the power of universal screening. Without it, he might have remained undiagnosed until advanced liver disease developed.
The CDC advises one-time screening for all adults aged 18 to 79. People with ongoing risk factors-such as injection drug use, HIV co-infection, or dialysis-should be screened annually.
Pregnant women should be tested during the first prenatal visit. The American College of Obstetricians and Gynecologists (ACOG) recommends this due to rising HCV rates among pregnant individuals, especially in rural areas.
Individuals with abnormal liver function tests should undergo screening even if they're outside the recommended age range. A single elevated ALT level raises suspicion for underlying liver disease, including HCV.
A positive screening result triggers a series of steps. First, confirm with NAT. Then assess liver health via elastography (FibroScan) or biopsy if needed. Determine genotype and viral load to select the right DAA therapy.
Treatment is effective and well-tolerated. Side effects are rare. Most regimens require no dose adjustments and have minimal drug interactions. The cost of DAAs has dropped since 2014, with many insurance plans covering them fully.
I've seen patients start treatment in a clinic while waiting for lab results. One woman in her 50s, diagnosed during a routine checkup, completed treatment in 12 weeks. She returned for follow-up and was cured. Her story underscores how accessible care can be when screening is routine.
People often confuse hepatitis C with hepatitis A. Hep A is caused by a different virus, transmitted through contaminated food or water. It's usually acute and resolves on its own. Hep C is chronic and spreads through blood contact.
Screening for HCV is not optional-it's a standard preventive measure. It saves lives by catching infection early, enabling cure before irreversible damage occurs.
Everyone aged 18 to 79 should have a hep c screening at least once. Those with risk factors should be tested annually. Early detection through screening is the most effective way to stop the spread of hepatitis C and prevent liver disease.